Sign In
Buy NVCT
$9.31
-0.200 (-2.10%)
At Close: Jun 03, 2026
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why
09:50am, Wednesday, 13'th Nov 2024
Nuvectis Pharma (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed throug
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
11:00am, Thursday, 07'th Nov 2024
The consensus price target hints at a 169.9% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
07:00am, Tuesday, 05'th Nov 2024
FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ
LONDON--(BUSINESS WIRE)---- $DRUG #Nasdaq--Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demons
FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of i
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
08:28am, Tuesday, 06'th Aug 2024
FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ
7 Penny Biotech Stocks to Triple Your Investment
06:10am, Tuesday, 28'th May 2024
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.
Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
10:56am, Friday, 24'th May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 229.3% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, t
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
08:30am, Thursday, 16'th May 2024
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative p
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
08:00am, Tuesday, 07'th May 2024
FORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
08:30am, Monday, 08'th Apr 2024
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant to
5 Healthcare Stocks to Buy for 2024
04:30pm, Tuesday, 02'nd Apr 2024
What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
08:00am, Tuesday, 19'th Mar 2024
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma to Present at the 36th Annual Roth Conference
08:00am, Friday, 15'th Mar 2024
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for Efficacy Complete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating Serio
